secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2024-10-21T23:59:59+00:00
Accession:  0001104659-24-110287
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics regains Nasdaq compliance with $50M market value requirement
------------------------------------------------------------------------------

- Received Nasdaq letter on Oct 21, 2024 confirming regained compliance with MVLS Requirement.
- Previously non-compliant as of July 11, 2024; had until Jan 7, 2025 to cure.
- Compliance now achieved; matter closed with no further action needed.
- Regained compliance ensures continued listing on The Nasdaq Global Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000110465924110287/0001104659-24-110287-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000110465924110287/tm2426597d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-110287

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer